We can’t show the full text here under this license.
Effectiveness, safety, and heart-related results of once-daily oral semaglutide in people with type 2 diabetes
Updated
Abstract
Oral semaglutide 7 and 14 mg once daily significantly reduced glycated haemoglobin () and body weight in patients with type 2 diabetes over treatment periods of up to 78 weeks.
- Oral semaglutide was tested in patients with type 2 diabetes with a duration of 3.5 to 15 years.
- The treatment showed better efficacy than placebo and standard glucose-lowering medications, including sitagliptin and empagliflozin.
- Patients experienced improvements in other diabetes-related endpoints, such as fasting plasma glucose.
- Oral semaglutide was well tolerated, with transient gastrointestinal events being the most common side effects.
- Cardiovascular safety was confirmed for oral semaglutide in patients with cardiovascular disease or high cardiovascular risk.
Simplified
Key numbers
−1.0%
Reduction
Change in for oral semaglutide vs. placebo in PIONEER 6.
−4.2 kg
Weight Loss
Mean weight reduction with oral semaglutide vs. placebo in patients with cardiovascular disease.
80%
Trial Completion Rate
Percentage of patients completing the PIONEER trials.